Skip to main content

Table 3. 2DE structural and functional parameters at 2 weeks

From: The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats

  Level Parameter Group
Control Empagliflozin
Apical level Systolic LVESA [mm2] 47.5 ± 4.3*** 54.4 ± 5.1***
LVIDs [mm] 7.1 ± 0.4*** 7.9 ± 0.5***
Diastolic LVEDA [mm2] 69.3 ± 4.4*** 74.3 ± 5.3***
LVIDd [mm] 8.8 ± 0.4*** 9.3 ± 0.4***
Function FS [%] 19.1 ± 3.3** 15.1 ± 4.0**
FAC [%] 33.6 ± 3.0*** 27.2 ± 3.5***
EF [%] 42.9 ± 5.4** 34.9 ± 6.4**
Papillary muscles level Systolic LVESA [mm2] 47.1 ± 3.4*** 52.4 ± 4.0***
LVIDs [mm] 7.8 ± 0.4*** 7.5 ± 0.5***
Diastolic LVEDA [mm2] 78.4 ± 3.8*** 80.2 ± 4.5***
LVIDd [mm] 9.5 ± 0.2*** 9.3 ± 0.3*** #
Function FS [%] 17.8 ± 2.7*** 20.1 ± 3.2**
FAC [%] 39.3 ± 2.9*** 35.7 ± 3.4**
EF [%] 40.2 ± 4.6*** 45.4 ± 5.4**
  1. Abbs. as in Table 2. ** P < 0.01 vs. baseline and *** P < 0.001 vs. baseline, # P < 0.05 vs. damage group
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840